Connect with us

Hi, what are you looking for?

Jewish Business News

Court

Teva Receives Sole Exclusivity for Generic Celebrex

Teva Receives Favorable Court Decision Regarding Generic Celebrex® Capsules; Teva Should Receive Sole Exclusivity for Generic Celebrex Capsules.

celebrex

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day “first-to-file” exclusivity for generic Celebrex (celecoxib) 100, 200 and 400 mg capsules.

On April 17th, Teva entered into a settlement agreement with Pfizer related to Teva’s generic version of Celebrex® (celecoxib) 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances.

Teva has received tentative approval from the U.S. Food and Drug Administration (FDA) for all strengths. Sales of Celebrex were $2.2 billion in the U.S. according to IMS data as of December, 2013.

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement